Immunomedics

Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.

BioMarin Pharmaceutical

Iovance Biotherapeutics

Fast-approaching catalysts could make these biotech stocks top performers this year.

These 3 Biotech Stocks Could Be Top Stocks in 2020

The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.

FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug

Prescription Drug User Fee Act (PDUFA) target action date set for June 2, 2020

Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer

ANI Pharma

Mirati Therapeutics

PTC Therapeutics

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

4 Drug/Biotech Outperformers That May Lose Steam in 2020

MORRIS PLAINS, N.J., Dec.  09, 2019  (GLOBE NEWSWIRE) --   Immunomedics, Inc.   (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the closing of its previously announced underwritten public offering of common stock. The total number of shares of common stock sold was 16,428,572, composed of 14,285,715 shares of common stock initially offered and an additional 2,142,857 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, in each case at a public offering price of $17.50 per share. The total net proceeds from the offering for Immunomedics are estimated to be approximately $272 million, after deducting underwriting discounts and commissions but before deducting other estimated offering expenses payable by the Company.

Immunomedics Announces  Closing of Public Offering of Common Stock

Immunomedics: Updates To Thesis, Buy The Secondary

Optimism is high that the company's lead pipeline candidate can secure an FDA OK.

Why Immunomedics Shares Surged 11.3% Today

MORRIS PLAINS, N.J., Dec.  04, 2019  (GLOBE NEWSWIRE) --   Immunomedics, Inc.   (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a public offering price of $17.50 per share, representing gross proceeds of approximately $250 million. In addition, Immunomedics has granted the underwriters a 30-day option to purchase up to 2,142,857 additional shares of common stock. The offering is expected to close on or about December 9, 2019, subject to customary closing conditions.

Immunomedics Announces  Pricing of Public Offering of Common Stock

Dynatrace Inc

Revance Therapeutics

Several companies raised capital on Wednesday.

Why Dynatrace, Revance Therapeutics, and Immunomedics Slumped Today

Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.

Immunomedics Resubmits Application for Breast Cancer Drug

MORRIS PLAINS, N.J., Dec.  03, 2019  (GLOBE NEWSWIRE) --   Immunomedics, Inc.   (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced it has commenced an underwritten public offering of $250,000,000 of shares of its common stock. In addition, Immunomedics expects to grant the underwriters a 30-day option to purchase up to an aggregate of an additional $37,500,000 of shares of common stock sold in connection with the offering at the public offering price.

Immunomedics Announces  Proposed Public Offering of Common Stock

MORRIS PLAINS, N.J., Dec.  03, 2019  (GLOBE NEWSWIRE) --   Immunomedics, Inc.   (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.

Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan

Immunomedics: A Breakthrough On Commercialization Could (Finally) Be Imminent

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

Implied Volatility Surging for Immunomedics (IMMU) Stock Options

AbbVie

Cigna

Agile Therapeutics

Cardinal Health

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

AbbVie, Cigna and Other Health Care Stocks With Recent Golden Crosses

Immunomedics' (IMMU) loss lags estimates in Q3. The company fails to generate any revenues at the same time.

Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3

Immunomedics, Inc. (IMMU) Management on Q3 2019 Results - Earnings Call Transcript

It's highly likely that Immunomedics' billion-dollar drug will finally be approved by the FDA.

1 No-Brainer Pharmaceutical Stock to Buy

Immunomedics, Inc. (NASDAQ: IMMU), a biopharma company focusing on the development of antibody-drug conjugates, or ADCs.

Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

Global Blood Therapeutics

Major binary events like late-stage clinical trial results or drug approvals offer high-risk, high-reward opportunities for those who can stomach the uncertainty.

2 Biotechs With Approaching Drug Approvals To Own Today

FedEx

Heron Therapeutics

KalVista Pharma

VBI Vaccines

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

5 Stocks to Buy Based on Insider Buying

Tenet Healthcare

Ulta Beauty

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys In The Past Week: Immunomedics, Tenet Healthcare, Ulta Beauty

Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.

Immunomedics (IMMU) Reports Interim Urothelial Cancer Data

The market isn't pleased with its latest clinical update.

Why Immunomedics Stock Is Sinking Today

Immunomedics Inc. (NASDAQ: IMMU) shares dropped sharply on Monday after the firm presented interim data from its midstage bladder cancer study at the European Society for Medical Oncology (ESMO) Annual Congress in Barcelona, Spain.

News for Immunomedics Stock (IMMU)